Export

EN
FR
Oxamniquine
Essential medicine status
Section:
6. Anti-infective medicines 6.1. Anthelminthics 6.1.3. Antischistosomals and other antitrematode medicines
ATC codes: P02BA02
EMLc
Indication
Schistosomiasis due to Schistosoma mansoni ICD11 code: 1G55.1
INN
Oxamniquine
Medicine type
Chemical agent
List type
Complementary (EML)
(EMLc)
Additional notes
oxamniquine is listed for use when praziquantel treatment fails.
Formulations
Oral > Liquid: 250 mg per 5 mL
Oral > Solid > capsule: 250 mg
EML status history
First added in 1977 (TRS 615)
Changed in 1979 (TRS 641)
Changed in 1997 (TRS 882)
Changed in 2005 (TRS 933)
Changed in 2007 (TRS 950)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Wikipedia
Oxamniquine
DrugBank
Oxamniquine
Summary of evidence and Expert Committee recommendations
Oxamniquine is recognized as second-line treatment for the treatment of schistosomiasis [praziquantel remains the first-line choice for all forms of schistosomiasis]. Noting that there are significant research gaps for medicines for children in this area, the EMLc Subcommittee decided to endorse this product as essential but highlighted the need for adequate studies to determine the effectiveness and safety of it in children.